VHL anticorps (N-Term)

N° du produit ABIN2788043

Détail du produit anti-VHL anticorps

Antigène: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Épitope: N-Term

Reactivité: Humain, Souris, Rat, Chien, Cobaye, Boeuf (Vache)

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VHL est non-conjugé

Application: Western Blotting (WB)

Séquence: EDGGEESGAE ESGPEESGPE ELGAEEEMEA GRPRPVLRSV NSREPSQVIF

Homologie: Cow: 93%, Dog: 93%, Guinea Pig: 100%, Human: 100%, Mouse: 100%, Rat: 100%

Attributs du produit: This is a rabbit polyclonal antibody against VHL. It was validated on Western Blot.

Purification: Affinity Purified

Information d'application

Indications d'application: Optimal working dilutions should be determined experimentally by the investigator.

Commentaires:

Antigen size: 172 AA

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Détails sur VHL

Antigène: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Autre désignation: VHL (VHL Produits)

Synonymes: anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992

Sujet: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Alias Symbols: HRCA1, RCA1, VHL1, pVHL
Protein Interaction Partner: ELC1, HIF1A, UBC, TPT1, MDFI, USP33, KAT2B, E2F1, TCP1, HSP90AA1, HSPA4, GLI1, EP300, SIRT1, AURKA, PARK7, RBX1, PDCD5, CUL2, TCEB2, TCEB1, AR, PIAS4, ILF3, HNRNPL, HNRNPA2B1, PRMT1, PRMT8, SON, SLC3A2, SLC2A1, RPS15A, RPL21, RPL5, HIST4H4, ACTB, VAPB, HI
Protein Size: 172

Poids moléculaire: 19 kDa

ID gène: 7428

NCBI Accession: NM_198156, NP_937799

Pathways: Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway